

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850 UNITED STATES Phone: +1-888-267-4436 Fax: +1-301-340-8606 techsupport@origene.com

OriGene Technologies GmbH

32052 Herford GERMANY Phone: +49-5221-34606-0 Fax: +49-5221-34606-11 info-de@origene.com

Schillerstr. 5

AM33249PU-T Monoclonal Antibody to IPO-38 Proliferation marker - Purified

Alternate names: IPO38
Quantity: 20 µg

Concentration: 0.2 mg/ml

Background:

IPO-38 antigen is present in the nuclei of proliferating cells such as Hodgkin's disease and non-Hodgkin's lymphomas, different forms of leukemias, breast and colorectal carcinomas, and PHA-stimulated lymphocytes. It is not expressed in the cells of non-stimulated lymphocytes and granulocytes. IPO-38 can be a useful marker of cell

proliferation during monitoring of tumor progression.

Host / Isotype: Mouse / IgM

Recommended Isotype

Controls:

SM13P

Clone: SPM260

Immunogen: Spleen cells of a patient with hairy cell leukemia.

Format: State: Liquid purified IgG fraction from Bioreactor Concentrate

Buffer System: 10mM PBS

Preservatives: 0.05% Sodium Azide

Stabilizers: 0.05% BSA

Applications: Flow Cytometry: $0.5-1 \mu g/10^6$ cells.

Immunofluorescence: 0.5-1 µg/ml.

Immunohistochemistry on Formalin-Fixed Paraffin Sections: 0.5-1 µg/ml for 30

minutes at RT.

Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate, pH

6.0, for 10-20 min followed by cooling at RT for 20 minutes.

Positive Control: Raji and PHA-stimulated (>12 hours) human or mouse lymphocytes.

Breast and colorectal carcinomas.

Other applications not tested. Optimal dilutions are dependent on conditions and

should be determined by the user.

Specificity: Recognizes a protein of 14-16kDa, which is a novel nuclear antigen of proliferating

cells. IPO-38 antigen is present in the nuclei of proliferating cells such as Hodgkin's disease and non-Hodgkin's lymphomas, different forms of leukemias, breast and colorectal carcinomas, and PHA-stimulated lymphocytes. It is not expressed in the

cells of non-stimulated lymphocytes and granulocytes.

IPO-38 can be a useful marker of cell proliferation during monitoring of tumor

progression.


Cellular Localization: Nuclear.

Species Reactivity: Tested: Human, Mouse, Rat.

Storage: Store undiluted at 2-8°C.

DO NOT FREEZE!

Shelf life: one year from despatch.



ORIGENE

General Readings:

- 1. Sidorenko SP, Vetrova EP, Iurchenko OV, Shlapatskaia LN, Berdova AG, Elenskaia AM, et al. [Monoclonal antibodies of the IPO series in studying and diagnosing malignant lymphoproliferative diseases]. Gematol Transfuziol. 1990 Apr;35(4):19-22. PubMed PMID: 2373343.
- 2. Mikhalap SV et al. Monoclonal antibody IPO-38 recognizes a novel nuclear antigen of proliferating cells. In Kishimoto T et al eds. Leukocyte Typing VI, p609-610, Garland Publishing, New York, 1997.
- 3. Mathews MB, Bernstein RM, Franza BR, Garrels JI. Identity of the proliferating cell nuclear antigen and cyclin. Nature. 1984 May 24-30;309(5966):374-6. PubMed PMID: 6145097.

Pictures:

Formalin-paraffin Human Tonsil stained with IPO38 Antibody Cat.-No AM33249PU (Clone SPM260).

